Cite
HARVARD Citation
Przespolewski, A. et al. (2021). Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy. Leukemia & lymphoma. 62 (7), pp. 1778-1781. [Online].